| Epigallocatechin-3-gallate (23, 24, 28,30,31,32,34,36) |
In humans (23, 24, 29,30,36) In vivo (32,34) In vitro (28,33) |
LNCaP (28,33) PC-3, and CWR22Rnu1 (28) LAPC-4 (33) TRAMP (32,34) |
EGCG (10-40 micromol/L) (28) 0.06% EGCG in tap water (32) Solution of 0.1% green tea polyphenols EGCG (62%) (34) Green tea extract capsules ,250 mg twice daily (36) |
Action on transcription factor Nf-kB inducing oxidative stress and downregolation of p53 (23, 24, 28, 29, 30) -antagonize the activity of IGF-1 and induce an receptorial antagonism for IGF-1 receptor (32,34) -inactivator of COX-2 (24, 31) |
| Curcumin |
In vitro (40,42,43) |
LNCaP (40,42) PC-3 (42,43) |
2-4 mg/L (about 5-10μM) (40) 15 µM (43) |
Increased the ratio of Bax to Bcl-2 proteins, decreased the activation of NFκB, PI3K/Akt and Stat3 pathways and cell migration (40) Down-regulation of transactivation and expression of AR, AP-1, NF-kB, and CREB-binding protein (CBP) (42) Inhibition of the IκB-kinase ,reduction in expression of CXCL1 and -2 ,downregulation of several important metastasis-promoting factors like COX2, SPARC and EFEMP (43) |
| Resveratrol |
In vitro (45,46) |
LNCaP (45,46,47) PC3 (45,46 ) and DU145 (45,46,47) |
2–40 μM (46); 1 µmol/L (47) |
Production of NO (45) Formation of free radicals (46) p53 activation and apoptosis (47) |
|
| Polyphenols and BPH |
|
| Compound |
Type of study |
N° patients |
Concentration used |
Outcome |
|
| Isoflavones (53) |
In humans (53,55) |
176 patients with |
40 mg of isoflavones (53) |
Superiority of isoflavones over placebo over 12 months[53] |
| Isoflavones and lignans (55) |
|
BPH (53) 25 patients (55) |
|
Isoflavones, but not lignans, have some influence the benign prostatic growth (55) |
